Media stories about Citius Pharmaceuticals (NASDAQ:CTXR) have trended somewhat positive this week, according to Accern Sentiment Analysis. The research group rates the sentiment of press coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Citius Pharmaceuticals earned a media sentiment score of 0.02 on Accern’s scale. Accern also gave news coverage about the company an impact score of 45.4998134523158 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.

Shares of Citius Pharmaceuticals (CTXR) traded down 3.02% during trading on Thursday, hitting $2.89. The stock had a trading volume of 13,263 shares. Citius Pharmaceuticals has a 52 week low of $2.75 and a 52 week high of $25.65. The stock’s 50 day moving average is $6.63 and its 200 day moving average is $6.50. The stock’s market capitalization is $14.55 million.

TRADEMARK VIOLATION WARNING: “Citius Pharmaceuticals (CTXR) Receives Coverage Optimism Score of 0.02” was originally published by Watch List News and is the sole property of of Watch List News. If you are accessing this piece on another publication, it was illegally stolen and reposted in violation of international copyright legislation. The original version of this piece can be accessed at

About Citius Pharmaceuticals

Citius Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company is engaged in the development and commercialization of critical care products targeting medical needs with a focus on anti-infective products, adjunctive cancer care, and prescription products. Its product candidates include Mino-Lok and Hydrocortisone-Lidocaine Cream.

Receive News & Ratings for Citius Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Citius Pharmaceuticals Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.